Advice
following an abbreviated submission:
faricimab (Vabysmo®) is accepted for use within NHSScotland.
Indication under review: for the treatment of adult patients with neovascular (wet) age-related macular degeneration (nAMD).
Faricimab offers an additional treatment choice in the therapeutic class of antineovascularisation agents for this indication.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice732KB (PDF)
Medicine details
- Medicine name:
- faricimab (Vabysmo)
- SMC ID:
- SMC2512
- Indication:
Neovascular (wet) aged-related macular degeneration (nAMD).
- Pharmaceutical company
- Roche
- BNF chapter
- Eye
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 December 2022